
USA - NASDAQ:GWPH -
The current stock price of GWPH is 218.96 null. In the past month the price increased by 0.6%. In the past year, price increased by 101.96%.
GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.
Gw Pharma ADR
SOVEREIGN HOUSE VISION PARK HISTON
CAMBRIDGE X0 CB24 9BZ
CEO: Justin Gover
Phone: 44-12-2326-6800
GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company's lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.
The current stock price of GWPH is 218.96 null. The price decreased by -0.15% in the last trading session.
GWPH does not pay a dividend.
GWPH has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Gw Pharma ADR (GWPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.86).
ChartMill assigns a technical rating of 7 / 10 to GWPH. When comparing the yearly performance of all stocks, GWPH is one of the better performing stocks in the market, outperforming 76.48% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to GWPH. GWPH has an average financial health and profitability rating.
Over the last trailing twelve months GWPH reported a non-GAAP Earnings per Share(EPS) of -1.86. The EPS decreased by -675% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -12.49% | ||
| ROA | -7.47% | ||
| ROE | N/A | ||
| Debt/Equity | 0.01 |